European Association for the Study of Diabetes

European Association for the Study of Diabetes Promoting excellence in diabetes care since 1965. The European Association for the Study of Diabetes e.V.
(1)

(EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. EASD is a networks for diabetologists with active members from all over the world. Membership is open to scientists, physicians, students, postdocs and fellows, allied health professionals and nurses who are interested in the field of diabetes or related diseases. The EASD Annual Meeting is one of the largest diabetes conferences in the world, attracting thousands of delegates each year. The scientific programme includes hundreds of talks, presentations and discussions on the latest results from basic and clinical diabetes research. EASD is also a leading player in postgraduate education having trained thousands of healthcare professionals through dedicated training courses and online education activities. Our award winning e-Learning platform, offers free access to courses developed with world-class experts in diabetes research and care. The Association is actively involved in producing and endorsing statements and guidelines translating the latest results from diabetes research into best practices in diabetes management. These statements and guidelines have proven to have significant visibility and substantial impact on health care, particularly when concerning statements on treatment and diagnostic criteria. By creating the Early Career Academy, EASD has increased its commitment to support, train, mentor, and create opportunities for scientists, clinicians, and students who are at an early or intermediate stage of their career. The European Foundation for the Study of Diabetes (EFSD) was founded by EASD in 2000 to stimulate diabetes research in Europe. EFSD offers support in all areas of diabetes research through a wide range of joint and stand-alone initiatives. Funding streams are available throughout the year and since inception, EFSD has committed over €120 million to diabetes research in Europe. EASD is also the publisher of Diabetologia, a major monthly international diabetes journal with an impact factor of 8.2 (2022). The journal publishes original clinical, translational and experimental research on all aspects of diabetes and related subjects. For more information about EASD, please visit: www.easd.org

👇🎥 In case you missed it! On World Diabetes Day 2025, the EASD Early Career Academy hosted a webinar on “The role of the...
21/11/2025

👇🎥 In case you missed it! On World Diabetes Day 2025, the EASD Early Career Academy hosted a webinar on “The role of the placenta in diabetes” with Prof. Gernot Desoye (Medizinische Universität Graz)

The full recording is now available. Watch now and learn how the placenta influences pregnancy outcomes in diabetes 👉 https://www.youtube.com/watch?v=i8RIp_EDpIY

🎙️ Can an oral GLP-1 receptor agonist deliver the same cardiovascular benefits we’ve only ever seen with injectables?In ...
21/11/2025

🎙️ Can an oral GLP-1 receptor agonist deliver the same cardiovascular benefits we’ve only ever seen with injectables?

In this week’s podcast interview, we hear the diabetologist’s take on the SOUL trial. Dr Rodica Busui (Oregon Health & Science University (OHSU) breaks down the first study to demonstrate cardiovascular risk reduction with an oral GLP-1 RA.

She explains:
✅ How the 14% MACE reduction compares with injectable formulations
✅ What this means for older adults and patients needing simpler, more accessible therapies
✅ New insights into heart failure phenotypes, especially HFpEF
✅ Why this data matters months after the annual meeting

A must-watch for clinicians, cardiometabolic teams, and anyone navigating the future of diabetes care.

👉 Listen here: https://www.easd.org/media-centre/podcasts/

🏆 We are pleased to recognise the 2025 recipients of the / Sanofi European Diabetes Research Programme on Autoimmunity...
20/11/2025

🏆 We are pleased to recognise the 2025 recipients of the / Sanofi European Diabetes Research Programme on Autoimmunity in type 1 diabetes.

This Programme supports investigators from non-profit institutions across Europe and associated countries, offering grants for basic and clinical research projects focused on autoimmunity in type 1 diabetes.

Its goal is to stimulate and accelerate European research aimed at enhancing understanding of autoimmunity in type 1 diabetes, including its pathogenesis, screening and monitoring, clinical course and potential interventions.

Learn more about the projects 👉 https://www.europeandiabetesfoundation.org/recipients/efsd-sanofi-research-programme-autoimmunity-in-t1d/

This programme is generously supported by Sanofi.

🌏 EASD in China 2025! On 1 November, the EASD in China 2025 Meeting brought highlights from the 61st EASD Annual Meeting...
20/11/2025

🌏 EASD in China 2025! On 1 November, the EASD in China 2025 Meeting brought highlights from the 61st EASD Annual Meeting in Vienna to Tianjin, continuing our mission to strengthen international dialogue and advance diabetes care in China.

Led by Prof. Chen Liming and joined by distinguished experts including Prof. Julia Mader, Prof. Janaka Karalliedde, and leading Chinese faculty, the programme explored major developments in Cardio-Kidney-Metabolic syndrome, GLP-1 and SGLT2 therapies and the next wave of technologies shaping metabolic disease management. This year’s meeting emphasised closing the gap between global evidence and clinical practice in China.

📌 Read the full report: https://www.easd.org/education/symposia/easd-in-china-2025/

Our thanks to all EASD faculty & Chinese colleagues for their support in making this initiative possible.

📣 Applications close soon! The 2nd Early Career Academy Meeting will bring together early-career researchers for three d...
19/11/2025

📣 Applications close soon! The 2nd Early Career Academy Meeting will bring together early-career researchers for three days of interactive lectures, workshops, discussions and hands-on training at the Deutsches Diabetes-Zentrum in Düsseldorf.

The meeting is designed to support emerging scientists and clinicians by strengthening research skills, encouraging collaboration, and providing access to leading experts in diabetes.

⏰ Application deadline: 2 December 2025

Explore the full programme and apply 👉 https://www.easd.org/academy/academy-activities/eca-meeting-2026/

19/11/2025

🚶‍♂️ Could GLP-1 receptor agonists offer new hope for people with peripheral artery disease (PAD) and type 2 diabetes?

➡️ In this Expert Insights episode, endocrinologist Assoc Prof. Alice Cheng discusses results from the STRIDE study and their implications for managing PAD in people living with type 2 diabetes.
❓How does semaglutide affect pain-free walking in people with PAD?
❓Why does functional improvement resonate more to patients than long-term risk stats?
❓What about sarcopenia?

📺 Watch the episode now on the EASD e-Learning platform: 🔗 https://easd-elearning.eu/episode/354/Evolving-role-of-GLP-RAs-in-diabetes-and-PAD.html

🧠 Grant Spotlight: Meet Dr. Jurga Laurencikiene (Karolinska Institutet), recipient of the EFSD/Novo Nordisk A/S Programm...
18/11/2025

🧠 Grant Spotlight: Meet Dr. Jurga Laurencikiene (Karolinska Institutet), recipient of the EFSD/Novo Nordisk A/S Programme for Diabetes Research in Europe grant.

Her project, “Type 2 diabetes and adipose tissue morphology: dual role and sex-specificity of the immune component,” explores how adipose tissue inflammation can be both detrimental (associated with chronic low-grade inflammation in obesity) and protective (supporting healthy expansion and guarding against T2D).

🔍 They identified a novel function for a well-none inflammatory factor IL-1beta as an important player in physiological adipose tissue expansion and defined inflammatory changes in adipose tissue caused by hormonal therapy.

🗣️ “EFSD grant enabled to perform an important part of my research. The communication with the foundation was easy and smooth,” Dr. Laurencikiene shared, highlighting the award's impact.

Check out the groundbreaking publications:
1️⃣ https://pubmed.ncbi.nlm.nih.gov/39261467/
2️⃣ https://pubmed.ncbi.nlm.nih.gov/38460092/

Explore EFSD opportunities 👉 https://europeandiabetesfoundation.org/programmes.html

Programme supported by Novo Nordisk.

The EASD Early Career Academy latest "Best of EASD 2025" episode is now live! Hear different impressions from early-care...
17/11/2025

The EASD Early Career Academy latest "Best of EASD 2025" episode is now live! Hear different impressions from early-career researchers sharing their highlights and key takeaways from the EASD Annual Meeting 2025 in Vienna.

This week, Dr Eugenia Martín Vázquez (ULB Center for Diabetes Research) walks us through what's new in type 1 diabetes research, from the role of beta and alpha cells to innovative beta cell imaging techniques and the latest advancements in stem cell-derived islets.

Watch the full episode on EASDtv 👉 https://youtu.be/udpCzkq8l-s

For the second episode of our highlights from the EASD Annual Meeting 2025 in Vienna series, we invited Dr. Eugenia Martin-Vazquez from the ULB Center for Di...

🎙️💊 Can a pill transform obesity and diabetes care? In the latest EASD TV Podcast, Dr. Sean Wharton and Dr. Nasreen Alfa...
14/11/2025

🎙️💊 Can a pill transform obesity and diabetes care? In the latest EASD TV Podcast, Dr. Sean Wharton and Dr. Nasreen Alfaris discuss the results of the ATTAIN trial, introducing Orforglipron (the first oral small molecule GLP-1 agonist).

From weight loss and prevention to global access and affordability, this conversation explores what could be a turning point in diabetes and obesity treatment.

🎧 Listen now: https://www.easd.org/media-centre/podcasts.html

✈️💙 Today is World Diabetes Day. This year’s theme, “Diabetes and the workplace,” highlights how diabetes affects profes...
14/11/2025

✈️💙 Today is World Diabetes Day. This year’s theme, “Diabetes and the workplace,” highlights how diabetes affects professionals across all fields even those working thousands of metres above the ground.

Did you know that in most countries, people living with diabetes cannot become or remain pilots or air traffic controllers (ATCOs)? Thanks to evolving regulations and research like the EASA - European Union Aviation Safety Agency Diabetes Project, led by Prof. Julia Mader of the Medizinische Universität Graz, the skies are becoming more inclusive! By testing how diabetes technologies perform under aviation conditions, the project is creating evidence-based frameworks that allow qualified pilots and air traffic controllers with diabetes to continue their work safely.

This World Diabetes Day, we celebrate the intersection of innovation, inclusion, and safety, proving that with the right research and technology, the sky is NOT the limit.

🔗👉 Read the full story: https://www.easd.org/worlddiabetesday2025/

🗣️💻 Tomorrow, join Prof. Gernot Desoye (Medizinische Universität Graz) and the EASD Early Career Academy for a webinar...
13/11/2025

🗣️💻 Tomorrow, join Prof. Gernot Desoye (Medizinische Universität Graz) and the EASD Early Career Academy for a webinar exploring how the placenta influences diabetes during pregnancy.

🗓️ 14 November 2025 | 🕛 16:00 CET

Gain insights into maternal-fetal interactions and their impact on both mother and child. Don’t miss this opportunity to learn from a leading expert!

Register now 👉 https://us06web.zoom.us/webinar/register/WN_5yWiAvvQSSutjto__7GVSw #/registration

🔁 The EASD Early Career Academy continues its series!

Next up on : Prof. Gernot Desoye (Medizinische Universität Graz) explores how the placenta influences pregnancy outcomes and fetal development.

Don’t miss this insightful session on 📅 14 November 2025 | 🕛 16:00 pm CET

Register now 👉 https://us06web.zoom.us/webinar/register/WN_5yWiAvvQSSutjto__7GVSw #/registration

Join us in congratulating the 2025 /Novo Nordisk A/S Programme for Diabetes Research in Europe recipients 🎉The award is...
13/11/2025

Join us in congratulating the 2025 /Novo Nordisk A/S Programme for Diabetes Research in Europe recipients 🎉

The award is a collaborative funding initiative to support both basic and clinical diabetes research across Europe, offering grants to researchers at non-profit institutions who are members of EASD. Its main goal is to foster innovation in all areas of diabetes research, from fundamental science to clinical applications, helping to advance knowledge and potential treatments for the disease.

Learn more about the projects 👉 https://www.europeandiabetesfoundation.org/recipients/efsd-nn-as-diab-research-europe/

This award programme is generously supported by Novo Nordisk.

Congratulations to all the recipients and we look forward to seeing the impact of your research!

Adresse

EASD/Rheindorfer Weg 3
Düsseldorf
40591

Öffnungszeiten

Montag 08:00 - 17:00
Dienstag 08:00 - 17:00
Mittwoch 08:00 - 17:00
Donnerstag 08:00 - 17:00
Freitag 08:00 - 17:00

Telefon

+492117584690

Webseite

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Association for the Study of Diabetes erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Praxis Kontaktieren

Nachricht an European Association for the Study of Diabetes senden:

Verknüpfungen

Teilen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Kategorie

Our Story

The Active Membership of the Association currently numbers more than 4,000 individuals from over 100 countries throughout the world. The Association also bestows Honorary Membership on any individual whose medical or scientific contribution to diabetes research has been outstanding; the first Honorary Member of the Association was Charles Best. The Association is governed by an Executive Committee chaired by the President. The Annual Meeting of the Association is held in a different European city each year. Abstracts are invited from members as well as non-members. All abstracts are anonymously reviewed by a Programme Committee, chaired by the Honorary Secretary. The EASD was one of the first international Associations to introduce the anonymous review of abstracts. The high quality of scientific research presented at the Annual Meetings is attested to by the increasing participation. The scientific programme of the Meeting, providing titles of the lectures and symposia, is made available online at a very early stage. Once confirmed, the speakers' names are made available and before the start of the Meeting all abstracts accepted for presentation can be accessed online. A search function assists the visitor in finding abstracts in their field of interest. Webcasts, poster presentations from the EASD Annual Meeting can be accessed via the EASD website.

EASD Postgraduate Education Courses have been organised by the Association since 1972 and, since then, over 25,000 medical professionals have taken part.

In 1999, the EASD increased its commitment to stimulate diabetes research in Europe by creating the European Foundation for the Study of Diabetes (EFSD).

Since its inception, EFSD has committed over Euro 100 million to diabetes research in Europe by various funding means.